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Abstract 
Each of the two type II domains and four larger fragments, containing one or two type II domains of fibronectin, have been expressed in Escherichia 
coli. A special vector, containing a fragment encoding the cleavage site for Factor X,, Ile-Glu-Gly-Arg, inserted immediately before the protein 
fragment of interest, was used. After treatment of the purified fusion proteins with reduced/oxidized glutathione, the correctly folded fibronectin 
fragments were released by proteolytic digestion with Factor X,. The largest fragment, consisting of two type II and two type I domains, was the 
only fragment able to bind to immobilized gelatin. 
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1. Introduction 
Fibronectin (FN) is a large multidomain/multifunc- 
tional glycoprotein found in blood plasma and in the 
extracellular matrix (reviewed in [l]). Its two, almost 
identical chains are built from three types of repeating 
units, the type I, type II and type III domains [2,3]. The 
type II domains, of which there are two, consist of ap- 
prox. 60 amino acid residues and contain four cysteinyl 
residues connected in a 1-3, 2-4 disulfide bridge pattern 
[4]. Type II domains have been identified in other pro- 
teins, such as blood clotting factor XII [5], bovine semi- 
nal fluid proteins PDC-109 and BSP A3 [6,71, insulin-like 
growth factor II receptor/mannose 6- phosphate recep- 
tor [8,9], mannose receptor [lo], 72 kDa and 92 kDa type 
IV collagenases [ 11,121. Five of these seven proteins (two 
have not been tested) can bind to denatured collagen 
(gelatin), and the type II domains are believed to play an 
important role in this binding. The two type II units of 
FN are unique to the 42 kDa gelatin-binding fragment 
(GBF) of FN, which also contains four type I domains 
in the sequence: 16-II,-II*-I,-Is-I9 [4] (numbers refer to the 
actual domain number, starting from the amino terminus 
of FN). Subfragments of the 42 kDa GBF (I&, 11,-I, 
and Is-I,) have been isolated [13,14] in order to further 
localize the gelatin- binding site. Of these were 11,-I, and 
*Corresponding author. Fax: (45) (86) 201 222. 
Abbreviations: FN, fibronectin; GBF, gelatin-binding fragment; HPLC, 
high-performance liquid chromatography; FX, plasma factor X; 
PMSF, phenylmethyl sulfonyl flouride; NTA, nitrilo-triacetic acid 
I,-&, strongly gelatin-binding and I& was weakly gela- 
tin-binding. Thus, separate gelatin-binding sites may be 
located on the type I and type II domains of the 42 kDa 
GBF. Other type II containing fragments of FN have 
been eroduced by gene expression in E. coli. These are 
II,, II,-II, and II,-II,-1,-I&, expressed as j%galactosi- 
dase fusion proteins [15], and they all bind immobilized 
gelatin. In contrast, one of the same fragments, II,-&, 
expressed by others [ 161, also as a /3-galactosidase fusion 
protein, did not bind gelatin, unless I, or the 14 amino 
terminal residues of I, was added to the carboxy-termi- 
nus of the fragment. 
In the mentioned, more or less conflicting reports, the 
type II, or type II2 domains were either bound to each 
other, to a type I domain or to a leader protein. In the 
present work, we have isolated recombinant ype II do- 
mains of FN that is free of type I domains and other 
fragments, and tested their ability to bind immobilized 
gelatin. Our results show, that only the largest fragment, 
16-II,-Q-I,, was able to bind to immobilized gelatin. 
None of the smaller fragments, consisting of one or two 
type II domains, bound to gelatin. The disulfide bridge 
patterns in the two small fragments, II, and 11,a (II, with 
a carboxy-terminal extension) were determined and 
found to be correct. 
2. Materials and methods 
2.1. Materials 
Restriction enzymes and chymotrypsin were purchased from Boerin- 
ger (Mannheim, Germany). A Qiagen kit for plasmid preparation and 
sequencing kit (ver. 2.0) used for dideoxy sequencing of cloned frag- 
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men&, were from USB (Cleveland, OH, USA). E. co/i N4830-1 cells 
were nurchased from Phamtacia (Sweden). Ni2+- NTA-Senharose was 
synth&ed as in [ 171. Gelatin was*coupi& to Sepharose 6B^ as decribed 
[18]. FX was isolated from bovine plasma and activated essentially as 
described in [lP] or purchased from Denzyme, Denmark. Trypsin was 
purchased from Worthington (Freehold, NJ, USA). Gelatin from swine 
skin (type I) was from Sigma (Sigma product no: G-2500). 
2.2. Plasmi& 
Plasmid pFH134, containing the cDNA insert of the entire 42 kDa 
GBF of FN 1201, was a kind gift from K. Vibe-Pedersen (Aarhus, 
Denmark). The E. coli expression plasmid pLcIIMLCH6 was con- 
structed from the vector pLcI1 [19,21] as described in [22]. 
2.3. Construction ~~pta~~~ expressing theJibronectin fragments 
DNA fragments encoding six type II containing fragments of FN 
(I,-11,-11,-I,, II,, II, I&a (II, with a six residue carboxy-terminal exten- 
sion peptide), &-II, and IIz-IT, see Fig. 1) were amplified from pFH134 
by PCR, using the primer pairs shown in Fig. 2. The amplified DNA 
fragments were purified by electrophoresis on 1% agarose, cleaved by 
BumHI and Hind111 and cloned into the BamHI/Z&dIII sites of 
pLciIMLCH6. CII encodes the 31 amino terminal residues of the hI1 
protein, MLC encodes the 118 amino terminal residues of human 
myosin light chain and H6 codes for six histidines, providing an afinity 
purification handle for a single-step urification on Ni*+- N’I’A-Sepha- 
rose [17]. 
2.4. Bacterial expression 
E. coli QY13 cells [IP] or N483@1 cells were transformed with the 
pLcIIMLCH6FXFIB expression vector, containing the inserted fi- 
bronectin fragment (FIB) and the factor X, recognition site, Be-Giy- 
Glu-Arg, (F@ introduced by the a~n~~~ ~~gonucleotid~ used 
in the PCR reaction lsee Fie. 21. The cells were mown at 30°C until 
A, = 0.8 and expre&on or the fusion protein ias induced by heat 
shock at 42°C (1.5 min) [19]_ Following expression at 37°C for 4-5 h, 
cells were harvested by centrifugation at 4’C and taken up in equal 
volumes of 10 mM Tris-HCl, 0.1 mM EDTA, pH 8.0 and detergent 
buffer [19]. Inclusion bodies were then isolated essentialIy as described 
[19]. After the final centrifugation the inclusion bodies were resus- 
pended in 10 mM Tris-HCl, 0.1 mM EDTA, pH 8.0 and mixed with 
the same volume of neutralized phenol and then sonicated. Two vol- 
umes of ethanol was added to the phenol extract and a crude protein 
fraction was obtained after centrifugation. 
2.5. Purification of the firsion protein 
The pillet cont&ing the &de protein was dissolved in 6 M guani- 
dinium chloride, 50 mM Tris-HCl, pH 8.0 containing 100 mM dithio- 
threitol and incubated overnight at 20°C. Insoluble cellular debris was 
removed by centrifugation &d the solution was gel-filtered on a Se- 
phadex G-25 column, equilibrated with 8 M urea, 1 M NaCl, 0.2 mM 
ascorbic acid, 50 mM Tris-HCl, pH 8.0 to remove the dithiothreitol. 
The fractions containing the protein were pooled and applied to a 
Ni*‘-NTA-Sepharose column, equilibrated with the same buffer. Fol- 
lowing extensive wash with the same buffer and with 6 M guanidinium 
chloride, 50 mM Tris-HCl, pH 8.0, the bound fusion protein was eluted 
with 8 M urea, 1 M NaCl, 0.2 mM ascorbic acid, 10 mM EDTA, 50 
mM Tris-HCl, pH 8.0. 
2.6. Refolding of the furion protein 
The purified fusion protein was reduced with 25 mM dithiotreitol and 
gel-filt&ed on a SephHdex G-25 column, equilibrated with 8 M urea, 
1 M NaCl, 2 mM dithiotreitol, 50 mM Tris-HCl, pH 8.0. Ten mM 
t~op~dyl-~u~thione (a blocking agent, reacting with free thiols) was 
added to the pooled fractions containing the protein, and the mixture 
was incubated at 4°C overnight with constant stirring. The blocked 
fusion protein was gel-filtered on a Sephadex G-25 column in 8 M urea, 
1 M NaCl, 50 mM Tris-HCl, pH 8.0. The pooled fractions containing 
the protein were reapplied to the Ni’+-NTA-Sepharose column (in the 
same buffer) to initiate the refolding on the column. First, 5 ml of 8 M 
urea, 1 M kaC1, 5 mM ascorbic acid, 50 mM Tris-HCl, pH 8.0 was 
annlied. then extensive wash with 1 M NaCl. 50 mM Tris-HCl. nH 8.7 
IA , ’ -. 
and incubation overnight in this buffer. The bound fusion protem was 
eluted with 1 M NaCl, 10 mM EDTA, 50 mM Tris-HCl, pH 8.7 and 
subjected to disulfide exchange (16 h, 20°C) by addition of reducedf 
oxidized giutathione at tinal concentrations of S mM/O.5 mM. 
2.7. Cleavage with factor X, 
The refolded fusion protein was cleaved with factor X, (16 h, 20 “C, 
l:loO, w/w) either directly in the elution buffer from the N?+-NTA- 
Sepharose column, or in 1 M NaCl, 50 mM Tris-HCl, pH 8.0, following 
gel filtration on Sephadex G-25. 
2.8. Affinity chromatography on gelatin-Sepharose 
The collagen a&ity of the individual type II containing FN frag- 
ments was assayed by aflinity chromatography on a gelatin-Sepharose 
column (1.6 x 11 cm), equilibrated with 50 mM Tris-HCl, 0.5 M NaCl, 
pH 7.5. Bound protein was eluted with 5 M urea, 50 mM Tris-HCl, 
0.5 M NaCl, pH 7.5 (Fig. 3A). 
2.9. Determination of dis@de bridges 
The two small fragments containing domains II, and I&a, respec- 
tively, were purified by reverse-phase HPLC (Pharmacia LKB HPLC 
syst&), on a Vydac c, column for II, and on a Nucleosil C!,, for I&a. 
SDS-PAGE (according to 1231) or amino terminal nrotein seauencinr! 
(using an Applied Bios&te&s i77A112OA sequencer\ was perfirmed t; 
identify the peaks containing II, and I&a, respectively. These were dried 
down, diss&ed in 0.1 M &moniu& bicarbonate-and igested, first 
with chvmotrvDsin (3 h, 37°C. 1:lOO: w/w1 and then with trvnsin (3 h. 
37”C, l-200; &iw). khsotry&in was i&&ted by PMSF iid try&d 
by soybean trypsin iuhibitor. Peptides were separated by HPLC, using 
a Nucleosil Cl8 column. Aliquota from each peak were hydrolyzed 
(6 M HCl, 16 h, 1lO’C) and the amino acid composition was deter- 
mined by a modification of the procedure described in [24]. Prior to 
hydrolyzation, performic acid oxidation was performed [2Sl to allow 
identification of cystines as cysteic acid. The bridge-containing peptides 
were sequenced, further treated with performic acid and rechromato- 
graphed by HPLC (Nucleosil C,*} to verify the shift from one to two 
peaks. These peaks were auaiyzed by amino acid analysis and sequenc- 
ing. 
3. Results and discussion 
Six fragments of fibronectin, containing type II do- 
mains, have been expressed in E. coli as 
cIIMLCH6FXFIB fusion products, isolated from inclu- 
sion bodies, denatured, reduced, purified and refolded/ 
reoxidized. Sequence specific cleavage with FX, liberated 
the fibronectin fragments. The six fibronectin fragments 
are: I&-II& II,, 112, I&a, III-II, and 11,-I, (I&a is II, 
with six extra residues (AAHEEI) in the carboxy termi- 
nus) and their position in the 42 kDa GBF of FN are 
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Fig. 1. Location of the six recombinant ype II containing fragments, 
Ib-11,-11,-I,, II,, II*, I&a (I&a is II, with a carboxy-terminal extension 
peptide, AAHEEI), II& and 11,-I,, in the gelatin-binding 42 kDa 
fragment of fibronectin. 
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Fx, 
1 275 419 
RamHI IEGRGHCVT b-=1-%2% GEWTC I AtezHindUI 
5= iX_TCGAGGGTA GGGGCCACTGTGK!ACA - 3’ . . . . . . . . . . . . . . . . . . _... 3= ~A~TA~GTAACXX AIIlEMGCCAGC - 5’ 
314 313 
I E G R T AV T Q TY II1 S F C T D I-I ter. 
5 *- CG~TCGAGGGTAGGACAGCTG’LWNXCAGACITAC - 3’ . . . . . . . . . . . . . 3’. GAGAAAGACGTWCTGGTG~GCCAGC - 5’ 
374 432 
I E G R TVL VQ T II2 G F C P M ter. 
5,. CG~TCGAGGGTAGGACTGTTITGG~GACT - 3’ . . . . . . . . . . . . . . . . . . . . . . . . . . 3= ACCCAAGAAGACGGGGTA ~GCCAGC-5 
374 438 
I E G R T VLVQ T A Ii E E I ter. 
5’- ~~~A~TA~A~~~AGA~ - 3’ . . . . . . . . . . . “;” . . . . . .._.. 3= AC~G~~AG~~~ - 5’ 
314 432 
I E G R T AV T Q TY “1-n, G F C PMter. 
S- CG~TCGAGGGTAGGACAGCIGTAACCCAGAC-ITAC - 3’ . . . . . . . . . . . . . . . . . . . 3= AWCAAGACGGGGTA -GCCAGC - 5’ 
374 479 
I E G R TVL VQ T =2-l, G E W T C I A ter. 
5’- CGW~TCGAGGGTAGGACIWTIWG~AGACT - 3’ . . . ..I........... 3’. CCCClTACCIGTACGTAACGG~GCCAGC - 5’ 
Fig. 2. Primer pairs used for PCR amplification of DNA fragments encoding the six fibronectin fragments hown in Fig. 1. The corresponding amino 
acid sequence is shown above each primer. The carboxy-terminal mino acid sequences (the right part) are translated from the strands complementary 
to the primers. Numbers refer to the protein sequence [Z]. Restriction sites are underlined. The arrow indicate the FX, cleavage site, 
shown in Pig. 1. DNA sequencing of the part of pFH134 
encoding IIz, showed CGA (coding for arginine, in posi- 
tion 380 of the protein sequence) instead of CAA (coding 
for glutamine) as reported by Kornblihtt et al. [20]. This 
brings the human FN sequence [20] in accordance with 
the bovine FN sequence [2] in this position, resulting in 
identical’type II, domains in the two species, indicating 
that this observed sequence difference is likely to repre- 
sent an original sequencing error rather than mutation 
of the cDNA clone. 
AfEnity c~omatography on gelatin-Sepharose 
1.0 
% 
1 
0.5 
showed that only the largest fragment, I~-II&-I,, 
bound to gelatin (Fig. 3A). When bound protein was 
diluted and reapplied to the gelatin-Sepharose column, 0 
complete rebinding was observed (Fig. 3B), confirming 
the specificity of the interaction. None of the smaller 
fragments bound to the gelatin-Sepharose column. This 
is in disagreement with the results of Bhnyai et al. [15], 
who reported that type II domain containing fragments, 
II, and III-I&, of FN, expressed as b-galactosidase fusion 
proteins, bind immobilized gelatin. Our findings also dis- 
agree with those of Ingham et al. [13,14] and Owens and 
Baralle [ 161, who report that the foment, II&, by itself 
1141, or as a/I-galactosidase fusion protein [16], can bind 
gelatin-Sepharose. The cause for the discrepancy is unre- 
solved, but may relate to different types or sources of 
B 
l.O- 
(I 
E - 
a 
0.5- 
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Fig. 3. (A) Affmity chromatography of the fibronectin fragment IsII,- 
II& on a gelatin-Sepharose column. ($8) Rechromatography of di- 
luted, bound protein from Fig. 3A. Arrows indicate the start of elution 
with buffer containing 5 M urea. 
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gelatin. Also it could be questioned if our fragments are 
correctly folded. To test correct folding in two of the 
smallest fragments, II1 and I&a, the disulfide bridge pat- 
terns were determined, and in both cases found to be 
correct. One may also speculate if a correct disulfide- 
bridge pattern is enough to ensure correct folding. We 
believe it is, and therefore the discrepancy between our 
results and those of Banyai et al. [15] may rely on un- 
specific binding of their fragments to the gelatin-sepha- 
rose or on the gelatin source as mentioned. 
In conclusion, our results do not support the conclu- 
sion of others [ 151, that one type II domain of fibronectin 
is capable of binding to gelatin on its own, similar to 
those of PDC-109 and BSP A3 [6,7]. In contrast, our 
data suggest hat the four-domain cluster 16-II,-II& is 
the smallest ype II containing fragment of fibronectin 
that harbours an authentic binding site for gelatin. 
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